Poster

Using the Ketogenic Diet as an Intervention to Treat Chronic Mental Disorders

Abstract: Background: In 2020, approximately 14.2 million US adults suffered with serious mental illness. Despite advances in pharmacological treatments, chronic psychiatric disorders rem...

08/20/2024

Valbenazine Improves Tardive Dyskinesia With or Without Concomitant Antipsychotic Therapy: A Meta-Analysis of Three Long-Term Valbenazine Trials

Abstract: Background: Valbenazine is a highly selective vesicular monoamine transporter 2 inhibitor indicated for tardive dyskinesia (TD), a persistent and potentially debilitating moveme...

08/20/2024

Willingness-to-Pay Analysis of Zuranolone in Major Depressive Disorder: a US Societal Perspective

Abstract: OBJECTIVES: Evaluate clinical and economic outcomes of zuranolone, an investigational drug, versus standard-of-care (SOC) antidepressants in adult patients with major depressive...

08/20/2024

The SOLARIS Protocol: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial Assessing Safety and Efficacy of TV-44749 (Olanzapine for Extended-Release Injectable Suspension Use) in Adults With Schizophrenia

Abstract: Background: Among patients with schizophrenia, nonadherence to oral antipsychotics increases relapse risk. Adherence may be improved with long-acting injectable (LAI) antipsycho...

08/20/2024

Matching-adjusted Indirect Treatment Comparison and Network Meta-Analysis of Zuranolone to Standard-of-care Antidepressant Therapies for the Acute Treatment of Adults with Major Depressive Disorder

Abstract: Background: Major depressive disorder (MDD) is a debilitating disease for which there is an unmet need for rapid-acting treatments. Zuranolone is an investigational oral, once-d...

08/20/2024

Total Cost of Care Following First-Line Antidepressant Treatment Failure Among Patients With Major Depressive Disorder in the United States

Abstract: OBJECTIVES: To evaluate total all-cause healthcare costs among US patients diagnosed with major depressive disorder (MDD) who failed first-line antidepressant treatment (ADT). ...

08/20/2024

Medication Adherence and Healthcare Resource Utilization in South Carolina Medicaid Beneficiaries with Schizophrenia or Schizoaffective Disorder: Long-acting Injectable vs. Oral Antipsychotics

Abstract: Background: Schizophrenia requires long-term treatment with antipsychotics; however, poor adherence to antipsychotic treatment can result in increased healthcare resource utiliz...

08/20/2024

Transitioning Patients to Long-Acting Injectable Antipsychotics: Attitudes and Perceptions of US Clinicians Based on a Hypothetical Case (Results from the DECIDE Survey)

Abstract: Background: Treatment with long-acting injectable antipsychotics (LAIs) reduces relapses in schizophrenia; however, best practices for introducing and transitioning patients to ...

08/20/2024

Patient Outcomes Post Hospitalization Discharge Among Patients With Schizophrenia Treated With a Long Acting Injectable or Switched to a New Oral Antipsychotic Medication

Abstract: Background: Low adherence to antipsychotic medication following a hospital discharge among patients with schizophrenia can lead to a higher risk of relapse and greater health ca...

08/20/2024

TV-46000—a Long-Acting Subcutaneous Antipsychotic (LASCA) for the Treatment of Schizophrenia: Local Tolerability and Injection Site Reactions

Abstract: Background: The phase 3 schizophrenia program for TV-46000, a long-acting subcutaneous antipsychotic (LASCA) formulation of risperidone, included the RISE efficacy study (NCT035...

08/20/2024